Kiadis Pharma appoints Dr. Robert Friesen as CSO
Kiadis Pharma N.V., a clinical-stage biopharmaceutical company, on Monday announced the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019.
Dr. Friesen will lead the Company’s science, discovery and pre-clinical development activities and will be instrumental in building the Companys scientific platform and identifying other programs for potential in-license. Dr. Friesen will report to Kiadis CEO Arthur Lahr and will be a member of the Companys management team.
Dr. Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple Research and Development (R&D) organisations. Dr. Friesen joins Kiadis from Ablynx where he was CSO until its acquisition by Sanofi. At Ablynx, Dr. Friesen oversaw a team of more than 300 people who were responsible for more than 40 development-stage product candidates across a wide range of diseases.
pixabay.com - geralt
SK Bioscience
wikioedia.org - Von http://web2.airmail.net/uthman/specimens/index.html, Gemeinfrei, https://commons.wikimedia.org/w/index.php?curid=841015